Patents by Inventor David Zahra

David Zahra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-NPY AND PYY ANTIBODIES AND USES THEREOF
    Publication number: 20150307599
    Abstract: The present disclosure provides proteins comprising antibody variable regions that bind specifically to NPY and PYY and uses thereof and methods of treating or preventing cancer or inducing an immune response by inhibiting NPY and PYY.
    Type: Application
    Filed: December 3, 2012
    Publication date: October 29, 2015
    Inventors: Martijn Bijker, Herbert Herzog, Fabienne McKay, Romain Rouet, Peter Schofield, David Zahra, Daniel Christ
  • Methods of inhibiting the interaction of C5aR with C5a with anti-C5aR antibodies
    Patent number: 8808701
    Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: August 19, 2014
    Assignee: G2 Inflammation Pty Ltd
    Inventors: Peter Whitfeld, David Zahra, Charles Reay Mackay
  • Humanized anti-C5aR antibodies
    Patent number: 8361468
    Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: January 29, 2013
    Assignee: G2 Inflammation Pty Ltd
    Inventors: Peter Whitfeld, David Zahra, Charles Reay Mackay
  • HUMANIZED ANTI-C5AR ANTIBODIES
    Publication number: 20120315275
    Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.
    Type: Application
    Filed: August 20, 2012
    Publication date: December 13, 2012
    Inventors: Peter Whitefeld, David Zahra, Charles Mackay
  • Humanized anti-C5aR antibodies
    Patent number: 8268972
    Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: September 18, 2012
    Assignee: G2 Inflammation Pty Ltd
    Inventors: Peter Whitfeld, David Zahra, Charles Mackay
  • Humanized Anti-C5aR Antibodies
    Publication number: 20110190477
    Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.
    Type: Application
    Filed: February 19, 2009
    Publication date: August 4, 2011
    Inventors: Peter Whitfeld, David Zahra, Charles Mackay
  • NEUTRALIZING ANTIBODIES
    Publication number: 20110044996
    Abstract: The present invention provides antibodies that bind, interact or otherwise associate with GM-CSF or a fragment, portion or part thereof and antagonize or neutralize GM-CSF activity. In accordance with embodiments of the present invention humanized monoclonal antibodies are generated which bind to human GM-CSF with high affinity and which inhibit the activity of GM-CSF.
    Type: Application
    Filed: May 23, 2008
    Publication date: February 24, 2011
    Inventors: Charles Mackay, David Zahra
  • EPITOPE FOR NEUTRALIZING ANTIBODIES
    Publication number: 20100297135
    Abstract: Provided herein are immunogenic peptides of GM-CSF comprising an amino acid sequence set forth in any one of SEQ ID NOs:2 to 6, or a portion thereof, and compounds and molecules that specifically interact with or bind to a region of GM-CSF located between, or corresponding to a region located between, about residues 89 and 117 of the human GM-CSF polypeptide sequence as set forth in SEQ NO:1.
    Type: Application
    Filed: November 12, 2008
    Publication date: November 25, 2010
    Applicant: CRC FOR ASTHMA AND AIRWAYS LTD.
    Inventors: Charles Mackay, David Zahra